You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK (GenomeWeb) – Japan's Pharmaceuticals and Medical Devices Agency has approved olaparib (Lynparza) as a first-line maintenance treatment after BRCA-mutated advanced ovarian cancer patients have responded to platinum-based chemotherapy.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.